According to Boston Scientific’s (BSX) estimates, around 110 million people around the world have been diagnosed with BPH (benign prostatic hyperplasia). To leverage growth opportunities in this large market, the company is focusing on training physicians to use its GreenLight laser therapy. Boston Scientific, however, expects some of its potential BPH patients to opt for minimally invasive therapies instead of a surgical option such as GreenLight therapy.
To bolster its position in the BPH segment, Boston Scientific announced the acquisition of NxThera in March. The deal added Rezūm, a system used for removing excess prostate tissue with the help of water vapor. In addition to being a complementary offering to the Boston Scientific’s GreenLight technology, Rezūm has expanded Boston Scientific’s BPH portfolio in the minimally invasive therapy area.
Minimally invasive therapies play a pivotal role in shifting BPH patients away from pharmaceuticals toward surgical or definitive treatment. Rezûm, which relieves symptoms through a simple in-office procedure, may witness solid uptake in future years. In the next article, we’ll discuss Boston Scientific’s growth prospects in the women’s health space.